UGDH and neoplasm: Indeed, it was recently shown that CB839 delayed tumour progression in mesenchymal GBM tumour-bearing mice, while having no effect in non-mesenchymal GBM tumour-bearing mice (Oizel et al., 2020), and obtained similar effects when using EGCG, a GDH inhibitor (Oizel et al., 2020).